OpenLM for Pharmaceuticals
Get the dosage right on your R&D software spend
From molecular modeling to process simulation and facility engineering, get complete usage visibility into your scientific and engineering software toolchain.
€60 billion
Estimated pharma R&D spend in Europe in 2025
Number links to source: EFPIA Key Data 2026
€287 billion
R&D invested by health industries worldwide in 2024, which is 19.9% of global business R&D
Number links to source: EU Industrial R&D Scoreboard 2025, via EFPIA
125,000
Estimated people employed in pharma R&D in Europe in 2025
Number links to source: EFPIA Key Data 2026
See your own pharmaceutical license usage in a live OpenLM demo.
Start Free Trial
Trusted by leading innovators





















Problem statement Your most expensive R&D software is also your least tracked
The "just in case" buffer
License counts are set at renewal and rarely revisited. Seats bought for the last program stay on the books long after it is cleared or shelved.
Pipeline peaks leave idle seats behind
Modeling, simulation and scale-up work surges around stage gates, then eases off. Licenses sized for the peak sit unused in between.
R&D budgets keep climbing
Health industries account for 19.9% of global business R&D, and European pharma R&D is estimated at €60 billion in 2025. As budgets grow, every idle modeling or simulation seat costs more. Without usage data, you can’t tell which seats earn their keep.
Where it breaks Where license gaps hit a yard
DISCOVERY AND DEVELOPMENT
Deadline risk
No seat is free when a study readout or regulatory submission can’t slip.
MULTI-SITE
Duplicated spend
Research labs, pilot plants and partner sites each hold their own licenses.
PROJECT COSTING
No cost visibility
Software costs are estimated per program, not allocated from real usage.
RENEWALS
Weak leverage
The vendor arrives with usage data. Most R&D teams don’t.
Case studies Pharmaceutical and Engineering: Software Case Studies
Pharmaceutical teams rely on tools like Ansys, Altair and Siemens to model, simulate and engineer. These licensed applications are costly and in uneven demand, so knowing how they are really used matters. The following are examples from engineering teams that show what visibility can do.
>€10,000
saved in the first year
After a corporate separation cut access to a shared Ansys pool, usage data showed where seats were hoarded. Peak demand fell from 155 to 140.
Siemens NX Medical devices
$20,000+
saved per year, with ROI in 6 months
About 1,000 users of scientific software needed clear visibility into how licenses were used. OpenLM usage data cut annual licensing cost.
Scientific software Higher education
$50,000+
saved in 30 days
Shared Ansys capacity was lost, and usage data showed where seats were hoarded. Peak demand fell from 155 seats to 90 to 100.
Ansys Energy
Usage visibility See usage vs. idle time
Session-level tracking
Track checkout, active and idle time per user, project and feature across 100+ license managers.
Automated idle harvesting
Set idle thresholds. Unused seats return to the pool without a ticket.
Per-project breakdown
Roll usage up by user, team or programme. Feed it straight into cost accounting.
Multi-site control One console, every lab, every program
Multi-site pooling
Replace separate site-by-site management with one shared view of design offices, depots and partner sites.
Programme-level cost data
Tie usage to project or contract codes so engineering software costs follow the work that drives them.
Reporting in minutes
Turn manual spreadsheet exports into scheduled reports for IT, engineering leads and finance.
Renewals Negotiate renewals with data, not guesses
Gap analysis
See where you are over-licensed or short of capacity, by product and site.
Audit readiness
Keep usage history on hand, so an audit request is a report, not a scramble.
True-up protection
Continuous monitoring keeps entitlements matched to peak usage.
License denials Every denied seat is a study that didn't run
Spot the pattern
Find the tools and time windows that cause the most denials.
Quantify the cost
Track denial duration and turn it into a figure engineering and finance both accept.
Fewer denials, not fewer seats
Idle seats go back to the pool before the next engineer asks.
OpenLM LicOps for HPC Run computational jobs only when the license is ready
LicOps checks each HPC job against your rules before it takes a machine. Jobs that fit start, the rest queue instead of failing at start-up, and every decision is logged with its reason.
Built for your pharmaceutical stack
Feature-level monitoring
100+ supported license managers, including FlexNet (FLEXlm), Sentinel RMS, DSLS, Autodesk and Bentley licensing:
By team What changes, by team
| Team | Without OpenLM | With OpenLM | OpenLM capability |
|---|---|---|---|
| IT / SAM | Limited visibility across environments | One view of usage across on-prem, SaaS, cloud and HPC | SaaS, Cloud & HPC Monitoring |
| IT / SAM | Idle and underused licenses increase costs | Idle seats and dongles are found and reclaimed for reuse | Harvesting, Reclamation & Dongle Monitoring |
| IT / SAM | License data is disconnected from IT workflows | License data flows into the IT workflows you already run | ITSM & MCP Integration |
| R&D and engineering leads | License denials and shortages disrupt work | Denials are tracked and flagged before they stall a project | Denial Tracking & Alerts |
| R&D and engineering leads | Difficult to control license access | Access is controlled by group, with usage visible per group | Access Control & Group Usage |
| Finance | License data is difficult to turn into decisions | Usage turns into reports that inform renewals and subscriptions | Advanced BI Reporting & Subscription Optimization |
| Executives and compliance | License usage must support compliance and audits | Usage history and access records are ready when an audit asks | Usage History, Access Records & Audit Reporting |
FAQ Frequently Asked Questions
Which pharmaceutical tools can OpenLM monitor?
OpenLM supports 100+ license managers, including FlexNet (FLEXlm). That covers the scientific computing, simulation and process engineering tools R&D teams run on network licenses.
Will reducing license counts cause more denials during a study or submission deadline?
Not if you size from real data. Denial reports show when and where demand peaks, and idle harvesting returns unused seats to the pool before the next request.
Can usage be tied to programs or projects for cost allocation?
Yes. Usage rolls up by user, team or project, so finance can allocate software costs to the programs that drive them.
Can usage data prepare us for an audit or true-up before it happens?
Yes. Continuous monitoring gives you usage history by product and site, so you can compare entitlements against actual peak use before a vendor asks.
Is OpenLM suitable for regulated pharma and biotech environments?
OpenLM is ISO/IEC 27001:2022 certified and SOC 2 Type II compliant.Â
Your next R&D software renewal is already on the calendar
See what your license usage really looks like before the vendor sends the notice.